论文部分内容阅读
目的探讨卵巢癌化疗耐药患者组织中染色体的变化特征,寻找或定位与卵巢癌化疗耐药密切相关的基因,以便对其耐药机制进一步研究。方法采用比较基因组杂交技术分析卵巢癌化疗耐药组(浆液性卵巢癌6例、黏液性卵巢癌3例、子宫内膜样卵巢癌2例、透明细胞癌1例,共12例)和化疗敏感组(浆液性卵巢癌5例、黏液性卵巢癌3例、子宫内膜样卵巢癌2例、透明细胞癌2例,共12例)两组癌细胞基因组的不平衡,即 DNA 丢失或扩增。结果化疗耐药患者组织中最常见的染色体 DNA 拷贝数增加的部位是3q,8q,20q,11q,17q,2p,1q;常见的染色体 DNA 拷贝数缺失的部位是9p,5q,10q,3p。其中17q 的增加,耐药组为66.7%,敏感组为16.7%;1q 的增加,耐药组为66.7%,敏感组为16.7%;3p 的丢失,耐药组为50.0%,敏感组为8.3%,在化疗耐药患者组织中表现更加明显。结论卵巢癌耐药患者组织中细胞染色体基因组最明显的改变为17q,1q 的增加以及3p的丢失,这些部位可能存在与卵巢癌化疗耐药密切相关的癌基因及抑癌基因。
OBJECTIVE: To investigate the chromosomal changes in the tissue of patients with chemoresistant ovarian cancer and to search for or locate the genes closely related to chemoresistance in ovarian cancer so that their resistance mechanism may be further studied. Methods A comparative genomic hybridization assay was used to analyze the chemoresistance group (6 cases of serous ovarian cancer, 3 cases of mucinous ovarian cancer, 2 cases of endometrioid ovarian cancer, 1 case of clear cell carcinoma, 12 cases) Groups (5 cases of serous ovarian cancer, 3 cases of mucinous ovarian cancer, 2 cases of endometrial-like ovarian cancer, 2 cases of clear cell carcinoma, a total of 12 cases) the two groups of cancer cell genome imbalance, DNA loss or amplification . Results The most common chromosomal DNA copy number was 3q, 8q, 20q, 11q, 17q, 2p, 1q in the tissues of chemotherapy-resistant patients. The common deletion region of chromosome DNA was 9p, 5q, 10q and 3p. The increase of 17q was 66.7% in the drug-resistant group and 16.7% in the sensitive group. The increase of 1q was 66.7% in the drug-resistant group and 16.7% in the sensitive group. The loss of 3p was 50.0% in the drug-resistant group and 8.3% in the sensitive group %, The performance of chemoresistant patients in the organization even more pronounced. Conclusions The most obvious change of chromosome number in the tissue of patients with drug-resistant ovarian cancer is the increase of 17q, 1q and the loss of 3p. There may be oncogenes and tumor suppressor genes closely related to chemoresistance in ovarian cancer.